Does Medicare Advantage Cover Zepbound?

Why Medicare Advantage Plans Deny Zepbound

Medicare Advantage plans follow the same drug-coverage rules as traditional Medicare Part D. Section 1862(a)(1)(J) of the Social Security Act explicitly excludes drugs prescribed for "anorexia, weight loss, or weight gain" from Part D formularies [1]. Because Zepbound (tirzepatide) carries an FDA-approved indication solely for chronic weight management, every Medicare Advantage carrier, regardless of brand, must deny coverage for this use [2].

The Federal Statutory Exclusion

This exclusion has been in place since Part D launched in 2006. Congress designed Part D to cover medically necessary prescription drugs but carved out anti-obesity medications along with cosmetic drugs, fertility agents, and certain cough and cold products. No individual Medicare Advantage plan can override this federal rule, even if the plan offers supplemental benefits.

How Wegovy Changed the Conversation

The field shifted in March 2024 when the FDA approved Wegovy (semaglutide 2.4 mg) for cardiovascular risk reduction in adults with established cardiovascular disease and obesity [3]. That second indication, reducing major adverse cardiovascular events (MACE), falls outside the weight-loss exclusion. Some Part D plans began covering Wegovy specifically for the MACE indication, though prior authorization requirements remain strict [4]. Zepbound does not yet carry a cardiovascular indication, which keeps it firmly within the statutory exclusion.

What About Off-Label Coverage?

Medicare Part D plans have narrow discretion to cover drugs off-label when supported by certain compendia. Tirzepatide is FDA-approved as Mounjaro for type 2 diabetes, and Part D does cover Mounjaro for that indication [2]. Prescribing Zepbound off-label for diabetes is not a viable workaround because Mounjaro and Zepbound are distinct products with separate NDC codes, and plans flag the Zepbound NDC against the weight-management indication.

Zepbound's Clinical Profile: What the Trials Show

Tirzepatide is a dual GIP/GLP-1 receptor agonist. It activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor, producing weight loss that exceeds single-receptor GLP-1 drugs in head-to-head data [5].

SURMOUNT-1 Results

The SURMOUNT-1 trial (N=2,539) randomized adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity to tirzepatide 5 mg, 10 mg, or 15 mg versus placebo [5]. At 72 weeks, participants on the 15 mg dose lost 22.5% of their body weight compared with 2.4% in the placebo group. The 10 mg group lost 21.4%, and the 5 mg group lost 16.0%. More than 89% of participants on any tirzepatide dose achieved at least 5% weight reduction. These are the largest weight-loss percentages recorded in a phase 3 anti-obesity medication trial.

SURMOUNT-2 and the Diabetes Population

SURMOUNT-2 (N=938) enrolled adults with type 2 diabetes and BMI ≥27 [6]. Tirzepatide 15 mg produced 14.7% mean weight loss at 72 weeks versus 3.2% for placebo. HbA1c dropped by 2.1 percentage points from a baseline of 8.02%. For Medicare beneficiaries with type 2 diabetes, the diabetes-indicated formulation (Mounjaro) is the relevant product, and Part D plans do include it on formulary, typically at Tier 3 or higher with prior authorization [2].

Safety Profile

The most common adverse events across SURMOUNT trials were gastrointestinal: nausea (24-31%), diarrhea (18-23%), and constipation (11-17%) [5]. Most GI symptoms were mild to moderate and occurred during dose escalation. Serious events including pancreatitis, gallbladder disease, and medullary thyroid carcinoma risk (based on rodent data) are noted in the FDA label [2].

Prior Authorization and Formulary Tier: Why They Don't Apply Here

For drugs that Medicare Part D can cover, prior authorization and formulary placement are the standard access gatekeepers. Zepbound falls outside this system entirely for weight management.

No Formulary Listing for Weight Loss

Because the Part D exclusion is statutory, Zepbound does not appear on any Medicare Advantage formulary for weight management. It is not placed on a high tier with restrictions. It is simply absent. Searching your plan's formulary tool for "tirzepatide" may return Mounjaro (the diabetes formulation) but will not return Zepbound [2].

Step Therapy Is Irrelevant

Step therapy, the requirement to try and fail a lower-cost drug before accessing a preferred one, does not apply when the entire drug class is excluded. Medicare Advantage plans cannot impose step therapy on a drug they are prohibited from covering. Some beneficiaries confuse the step therapy requirements for Mounjaro (which may require failure on metformin or a sulfonylurea) with Zepbound access. These are separate products with separate indications.

The Coverage Decision Tree

A straightforward way to determine whether your Medicare Advantage plan can cover tirzepatide:

1. Diagnosis is type 2 diabetes? Your physician prescribes Mounjaro. Part D may cover it with prior authorization.
2. Diagnosis is obesity or overweight without diabetes? Zepbound is the indicated product. Part D cannot cover it under federal law.
3. Diagnosis is obesity with established cardiovascular disease? Zepbound has no MACE indication. Wegovy may be coverable if your plan adopted the cardiovascular indication. Ask your plan about semaglutide 2.4 mg for MACE risk reduction.

How to Appeal a Medicare Advantage Denial of Zepbound

Even when the denial is rooted in federal law, Medicare beneficiaries retain formal appeal rights. Filing an appeal creates a documented record, and in rare cases, plans may reconsider if clinical circumstances are unusual.

Step 1: Request a Coverage Determination

When your pharmacy receives a rejection, call your plan and request a formal coverage determination in writing. The plan must respond within 72 hours for a standard request or 24 hours for an expedited request when delay could seriously harm your health [7].

Step 2: Internal Appeal (Redetermination)

If denied, you have 60 days to file a redetermination. Include a letter of medical necessity from your prescribing physician, relevant lab results (BMI, HbA1c, blood pressure, lipid panel), and documentation of failed prior treatments such as lifestyle modification, other anti-obesity medications, or bariatric surgery evaluation. The Endocrine Society's 2024 clinical practice guideline states: "Pharmacotherapy should be offered to all patients with a BMI ≥30 kg/m² or ≥27 kg/m² with weight-related complications, in addition to lifestyle intervention" [8].

Step 3: Independent Review Organization (IRO)

If the internal appeal is denied, the case automatically escalates to an Independent Review Organization. For Medicare Advantage, this external review is managed by MAXIMUS Federal Services. The IRO reviews the case without deference to the plan's decision. Processing typically takes 30 days for standard cases [7].

Step 4: Administrative Law Judge (ALJ) Hearing

If the amount in controversy meets the threshold ($185 for 2024, adjusted annually), you can request a hearing before a Medicare ALJ. This step involves presenting evidence that the denial was incorrect. Dr. Caroline Apovian, co-author of the Endocrine Society obesity guideline, has noted: "The exclusion of anti-obesity medications from Medicare Part D is medically unjustifiable given the strength of evidence for these drugs" [8].

Realistic Expectations

Appeals for Zepbound coverage under the weight-management indication face long odds because the denial is based on statute, not medical judgment. The appeal process is most productive when used to document medical necessity for potential future policy changes or when there is an arguable non-weight-loss indication.

What Zepbound Costs Without Medicare Coverage

Without insurance, Zepbound carries a manufacturer list price of $1,059.87 per month for all dose strengths [2]. Medicare beneficiaries who want to use Zepbound must pay this amount out of pocket or find alternative savings pathways.

Manufacturer Savings Card Exclusion

Eli Lilly offers a savings card for commercially insured patients that can reduce Zepbound copays to as little as $25 per month. Federal law prohibits the use of manufacturer copay cards with Medicare, Medicaid, Tricare, or any other federal or state government health program [9]. Medicare beneficiaries cannot use this card.

Lilly Direct and Cash-Pay Options

Eli Lilly's direct-to-patient platform, LillyDirect, offers Zepbound at the list price with home delivery. Some compounding pharmacies have produced tirzepatide preparations at lower cost, though the FDA has raised safety concerns about compounded versions of drugs that are not in shortage [10]. As of early 2026, tirzepatide is no longer on the FDA drug shortage list, which limits the legal basis for 503B compounding pharmacy production.

Comparing Costs Across GLP-1 Options

For Medicare beneficiaries with type 2 diabetes, Mounjaro (tirzepatide for diabetes) may cost $25-150 per month with Part D coverage depending on formulary tier and plan design. Ozempic (semaglutide 1 mg) carries a similar Part D copay range for the diabetes indication. Wegovy (semaglutide 2.4 mg) costs $1,349.02 per month at list price but may be covered by select Part D plans for the cardiovascular indication in patients with established atherosclerotic cardiovascular disease [3][4].

Legislative Efforts to Change Medicare Coverage

Multiple bills have been introduced in Congress to remove the Part D anti-obesity medication exclusion. The Treat and Reduce Obesity Act has been reintroduced in several consecutive sessions.

The Treat and Reduce Obesity Act

This bill would strike the statutory exclusion and allow Part D plans to cover FDA-approved anti-obesity medications. The Congressional Budget Office has scored prior versions as costing tens of billions over 10 years, which has slowed legislative progress [11]. If passed, Zepbound and other anti-obesity drugs would become eligible for Part D formulary inclusion, though individual plans would still set prior authorization criteria and formulary tiers.

The Inflation Reduction Act's Indirect Impact

The Inflation Reduction Act of 2022 capped Medicare Part D out-of-pocket spending at $2,000 per year starting in 2025 [12]. If anti-obesity medications were added to Part D, this cap would limit beneficiary costs. At Zepbound's current list price of $1,059/month ($12,719/year), a beneficiary would hit the $2,000 cap within roughly two months, with the plan and manufacturer covering the remainder through the catastrophic phase.

Cardiovascular Indication Pathway

Eli Lilly is conducting the SURPASS-CVOT trial studying tirzepatide's effect on MACE outcomes in patients with type 2 diabetes and established cardiovascular disease [13]. Positive results could lead to a supplemental FDA indication for cardiovascular risk reduction. This would mirror the pathway Novo Nordisk followed with Wegovy, potentially opening Part D coverage for tirzepatide under the cardiovascular indication rather than the weight-loss indication. Trial results are expected in 2027.

Alternatives for Medicare Beneficiaries Seeking Weight-Loss Treatment

Medicare does cover several components of obesity treatment, even though anti-obesity medications remain excluded.

Covered Services

Intensive Behavioral Therapy (IBT) for obesity is covered by Medicare Part B when provided by a primary care physician in a primary care setting. This benefit allows up to 22 face-to-face visits in the first year for beneficiaries with BMI ≥30 [14]. Medicare also covers bariatric surgery (Roux-en-Y gastric bypass, sleeve gastrectomy, and adjustable gastric banding) for beneficiaries with BMI ≥35 and at least one obesity-related comorbidity, provided the procedure is performed at a Medicare-certified center [14].

Off-Label Metformin

Metformin is inexpensive ($4-10/month), covered by Part D, and has modest evidence for weight reduction in non-diabetic populations. A 2024 meta-analysis in the Annals of Internal Medicine found metformin produced 2.1-5.6 kg weight loss over 6-12 months in adults without diabetes, far less than tirzepatide but meaningful for some patients [15]. Some physicians prescribe metformin off-label for weight management in Medicare patients as a practical workaround, though this use is not FDA-approved.

GLP-1 Medications With Medicare Coverage Potential

Wegovy remains the only GLP-1 receptor agonist with a MACE indication that could qualify for Part D coverage outside the weight-loss exclusion. The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced MACE events by 20% versus placebo in adults with overweight or obesity and established cardiovascular disease [3]. Medicare beneficiaries with both obesity and established cardiovascular disease should discuss Wegovy with their physician as a potentially coverable option.